Opium use and risk of lung cancer: A multicenter case-control study in Iran.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
15 01 2023
Historique:
revised: 10 07 2022
received: 29 04 2022
accepted: 11 07 2022
pubmed: 1 9 2022
medline: 23 11 2022
entrez: 31 8 2022
Statut: ppublish

Résumé

Opium use was recently classified as a human carcinogen for lung cancer by the International Agency for Research on Cancer. We conducted a large, multicenter case-control study evaluating the association between opium use and the risk of lung cancer. We recruited 627 cases and 3477 controls from May 2017 to July 2020. We used unconditional logistic regression analyses to estimate the odds ratios (OR) and 95% confidence intervals (CI) and measured the association between opium use and the risk of lung cancer. The ORs were adjusted for the residential place, age, gender, socioeconomic status, cigarettes, and water pipe smoking. We found a 3.6-fold risk of lung cancer for regular opium users compared to never users (95% CI: 2.9, 4.6). There was a strong dose-response association between a cumulative count of opium use and lung cancer risk. The OR for regular opium use was higher for small cell carcinoma than in other histology (8.3, 95% CI: 4.8, 14.4). The OR of developing lung cancer among opium users was higher in females (7.4, 95% CI: 3.8, 14.5) than in males (3.3, 95% CI: 2.6, 4.2). The OR for users of both opium and tobacco was 13.4 (95% CI: 10.2, 17.7) compared to nonusers of anything. The risk of developing lung cancer is higher in regular opium users, and these results strengthen the conclusions on the carcinogenicity of opium. The association is stronger for small cell carcinoma cases than in other histology.

Identifiants

pubmed: 36043555
doi: 10.1002/ijc.34244
doi:

Substances chimiques

Opium 8008-60-4

Types de publication

Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

203-213

Informations de copyright

© 2022 UICC.

Références

Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249.
Malhotra J, Malvezzi M, Negri E, La Vecchia C, Boffetta P. Risk factors for lung cancer worldwide. Eur Respir J. 2016;48:889-902.
Mons U, Gredner T, Behrens G, Stock C, Brenner H. Cancers due to smoking and high alcohol consumption: estimation of the attributable cancer burden in Germany. Dtsch Arztebl Int. 2018;115:571.
IARC Monograph Volume 126 Working Group. Carcinogenicity of opium consumption. Lancet Oncol. 2020;21:1407-1408.
World Drug Report 2019 (United Nations Publication, Sales No. E.19.XI.8).
Couraud S, Zalcman G, Milleron B, Morin F, Souquet P-J. Lung cancer in never smokers - a review. Eur J Cancer. 2012;48:1299-1311.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.
Zhou F, Zhou C. Lung cancer in never smokers-the east Asian experience. Transl Lung Cancer Res. 2018;7:450-463.
Peddireddy V. Lung cancer incidence in never smokers: genetic and gender basis. Gene Rep. 2016;4:198-207.
MacLennan R, Da Costa J, Day NE, Law CH, Ng YK, Shanmugaratnam K. Risk factors for lung cancer in Singapore Chinese, a population with high female incidence rates. Int J Cancer. 1977;20:854-860.
Masjedi MR, Naghan PA, Taslimi S, et al. Opium could be considered an independent risk factor for lung cancer: a case-control study. Respiration. 2013;85:112-118.
Naghibzadeh-Tahami A, Marzban M, Yazdi-Feyzabadi V, et al. Is opium use associated with an increased risk of lung cancer? A case-control study. BMC Cancer. 2020;20:1-8.
Sheikh M, Shakeri R, Poustchi H, et al. Opium use and subsequent incidence of cancer: results from the Golestan Cohort Study. Lancet Glob Health. 2020;8:e649-e660.
Hadji M, Rashidian H, Marzban M, et al. The Iranian Study of Opium and Cancer (IROPICAN): rationale, design, and initial findings. Arch Iran Med. 2021;24:167-176.
Mohebbi E, Rashidian H, Tahami AN, et al. Opium use reporting error in case-control studies: neighborhood controls versus hospital visitor controls. Med J Islam Repub Iran. 2021;35:60.
Rashidian H, Hadji M, Marzban M, et al. Sensitivity of self-reported opioid use in case-control studies: healthy individuals versus hospitalized patients. PLoS One. 2017;12:e0183017.
Amin-Esmaeili M, Rahimi-Movaghar A, Sharifi V, et al. Epidemiology of illicit drug use disorders in Iran: prevalence, correlates, comorbidity and service utilization results from the Iranian Mental Health Survey. Addiction. 2016;111:1836-1847.
Mohebbi E, Hadji M, Rashidian H, et al. Opium use and the risk of head and neck squamous cell carcinoma. Int J Cancer. 2021;148:1066-1076.
Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons; 2000.
Bidary MZ, Sahranavard M, Rezayat AA, et al. Opium as a carcinogen: a systematic review and meta-analysis. EClinicalMedicine. 2021;33:100768.
Mohebbi E, Kamangar F, Rahimi-Movaghar A, et al. An exploratory study of units of reporting opium usein Iran: implications for epidemiologic studies. Arch Iran Med. 2019;22:541-545.
Lee PN, Forey BA, Coombs KJ. Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer. BMC Cancer. 2012;12:385.
Belani CP, Marts S, Schiller J, Socinski MA. Women and lung cancer: epidemiology, tumor biology, and emerging trends in clinical research. Lung Cancer. 2007;55:15-23.
Freedman ND, Leitzmann MF, Hollenbeck AR, Schatzkin A, Abnet CC. Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. Lancet Oncol. 2008;9:649-656.
Park B, Kim Y, Lee J, Lee N, Jang SH. Sex difference and smoking effect of lung cancer incidence in Asian population. Cancer. 2021;13:113.
Ebbert JO, Yang P, Vachon CM, et al. Lung cancer risk reduction after smoking cessation: observations from a prospective cohort of women. J Clin Oncol. 2003;21:921-926.
Song YM, Sung J, Cho HJ. Reduction and cessation of cigarette smoking and risk of cancer: a cohort study of Korean men. J Clin Oncol. 2008;26:5101-5106.
Ghahremani H, Jarrahi AM, Salami S. Cancer and opium addiction. Asian Pac J Cancer Biol. 2019;4:69-70.
Whiteman DC. Regular opium use and subsequent incidence of cancer. Lancet Glob Health. 2020;8:e613-e614.
Broggio J, Bannister N. Cancer survival by stage at diagnosis for England. Newport, UK: Office for National Statistics; 2016.
Rashidian H, Zendehdel K, Kamangar F, Malekzadeh R, Haghdoost AA. An ecological study of the association between opiate use and incidence of cancers. Addict Health. 2016;8:252-260.

Auteurs

Hamideh Rashidian (H)

Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.

Maryam Hadji (M)

Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Health Sciences Unit, Faculty of Social Sciences, Tampere University, Tampere, Finland.

Mahin Gholipour (M)

Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran.

Ahmad Naghibzadeh-Tahami (A)

Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.

Maryam Marzban (M)

Clinical Research Development Center, The Persian Gulf Martyrs, Bushehr University of Medical Science, Bushehr, Iran.
Department of Public Health, School of Public Health, Bushehr University of Medical Science, Bushehr, Iran.

Elham Mohebbi (E)

Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Pathology and Stem Cell Research Center, Kerman University of Medical Sciences, Kerman, Iran.

Roya Safari-Faramani (R)

Social Development and Health Promotion Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Mahdieh Bakhshi (M)

Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.

Monireh Sadat Seyyedsalehi (M)

Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Bayan Hosseini (B)

Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
International Agency for Research on Cancer, Lyon, France.

Reza Alizadeh-Navaei (R)

Gastrointestinal Cancer Research Center, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.

Habib Emami (H)

National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Ali Akbar Haghdoost (AA)

Social Determinants of Health Research Center, Institute for Futures Studies in Health, Kerman, Iran.
Regional Knowledge HUB for HIV/AIDS Surveillance, Research Centre for Modelling in Health, Institute for Future Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.

Abbas Rezaianzadeh (A)

Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Abdolvahab Moradi (A)

Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran.

Alireza Ansari-Moghaddam (A)

Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.

Azim Nejatizadeh (A)

Tobacco and Health Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.

Soodabeh ShahidSales (S)

Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Alireza Rezvani (A)

Hematology Research Center, Shiraz University of Medical Science, Fars, Iran.

Mohammad Hasan Larizadeh (MH)

Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.

Farid Najafi (F)

Social Development and Health Promotion Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Research Center for Environmental Determinants of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Hossein Poustchi (H)

Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.

Mohammad Ali Mohagheghi (MA)

Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.

Paul Brennan (P)

International Agency for Research on Cancer, Lyon, France.

Elisabete Weiderpass (E)

International Agency for Research on Cancer, Lyon, France.

Joachim Schüz (J)

International Agency for Research on Cancer, Lyon, France.

Eero Pukkala (E)

Health Sciences Unit, Faculty of Social Sciences, Tampere University, Tampere, Finland.
Finnish Cancer Registry-Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland.

Neal D Freedman (ND)

Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.

Paolo Boffetta (P)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Stony Brook Cancer Center, Stony Brook University, Stony Brook, New York, USA.

Reza Malekzadeh (R)

Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Digestive Oncology Research Center, Digestive Diseases Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Arash Etemadi (A)

Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Digestive Oncology Research Center, Digestive Diseases Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Afarin Rahimi-Movaghar (A)

Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, Iran.

Farin Kamangar (F)

Department of Biology, School of Computer, Mathematical, and Natural Sciences, Morgan State University, Baltimore, Maryland, USA.

Kazem Zendehdel (K)

Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Cancer Biology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH